Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: Comparison of grading systems

• Published in: Biology of blood and marrow transplantation 2002-01, Vol.8 (7), p.387-394
• Main Authors: MacMillan, Margaret L, Weisdorf, Daniel J, Wagner, John E, DeFor, Todd E, Burns, Linda J, Ramsay, Norma K.C, Davies, Stella M, Blazar, Bruce R
• Format: Article
• Language: English
• Subjects: Acute Disease; Adolescent; Adult; Anti-Inflammatory Agents - administration & dosage; Child; Child, Preschool; Female; Graft vs Host Disease - drug therapy; Graft vs Host Disease - pathology; Graft vs Host Disease - prevention & control; Hematopoietic Stem Cell Transplantation - adverse effects; Hematopoietic Stem Cell Transplantation - mortality; Humans; Infant; Male; Middle Aged; Opportunistic Infections - etiology; Prednisone - administration & dosage; Prospective Studies; Retrospective Studies; Risk Factors; Severity of Illness Index; Steroids - administration & dosage; Survival Analysis; Transplantation, Homologous - adverse effects; Transplantation, Homologous - mortality
• ISSN: 1083-8791; 1523-6536
• DOI: 10.1053/bbmt.2002.v8.pm12171485

Acute GVHD remains a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). In a retrospective analysis, the response of 443 HSCT patients who received prednisone, 60 mg/m2, for 14 days followed by an 8-week taper, as initial therapy for acute GVHD from 1990 through 1999 at a single institution was examined. Median patient age was 29.0 years (range, 0.3-60.3 years), with 40% of patients or = 28 days) complete response observed in 35% and partial response observed in 20% of patients. Patients with acute lower gastrointestinal GVHD (+/- other organ involvement) had lower response rates. In multivariate logistic regression analysis, recipients of related donor grafts and recipients of GVHD prophylaxis other than methotrexate alone had the highest likelihood of overall response. Initial Minnesota GVHD grade or Consensus GVHD grade was not associated with significant differences in overall response, whereas patients with an initial IBMTR grade of B or C had a higher likelihood of response. Chronic GVHD developed in 42% of patients by 1 year after HSCT. The probability of survival at 1 year after initiation of steroid therapy was 53% (95% confidence interval, 48%-58%). In Cox regression analysis, factors associated with better survival included patients' youth, receipt of related or HLA-matched unrelated grafts, and administration of GVHD prophylaxis other than T-cell depletion in all 3 grading systems. Lower initial GVHD grade (I-II or A-B) led to better survival. These data suggest that steroids provide an active but inadequate therapy for acute GVHD, especially with higher grade GVHD. More effective prophylaxis and therapy for acute GVHD is needed for mismatched unrelated donor recipients and for those with severe GVHD. Biol Blood Marrow Transplant 2002;8(7):387-94.